Hoofddorp, the Netherlands, 8 August 2020. IGEA Pharma N.V. (SIX: IGPH) today announced the signing of a letter of intent, binding upon the parties in terms, with Blue Sky Natural Resources LTD (“BSNR”), a privately held company specialized in transforming vegetable matrices into innovative and high tech value products for the health, nutraceutical and cosmeceutical industry, to combine the two companies’ businesses, subject to the approval by both companies’ respective general meetings and certain other closing conditions as detailed below. The transaction is structured through a contribution in-kind by the BSNR shareholders of at least 75% of the BSNR shares into IGEA by subscribing newly issued shares in a dedicated share capital increase of IGEA. The combination will create an EU headquartered and SIX-listed company with an innovative early-stage commercial and a strong development pipeline focusing on health prevention and nutraceutical solutions including hemp, ikuvia and other vegetable matrices extracts from CO2 supercritical technology.
Hoofddorp, the Netherlands, 7 August 2020. IGEA Pharma N.V. (SIX: IGPH) today announced the resignation of Mr. Marco Seniga from its board of directors for personal reasons related to his retirement. Seniga also terminated his engagement with the company as director of marketing and
Minutes of the Extraordinary General Meeting of IGEA Pharma N.V., a public limited company (naamloze vennootschap), having its registered office in Amsterdam (the Netherlands) and address at (2132 WT) Hoofddorp, Siriusdreef 17, registered with the Commercial Register of the Chamber of Commerce under number 70212821, held at Hoofddorp Transpolis, Polarisavenue 1, (2123 JH) Hoofddorp (the Netherlands) on 3 July 2020.
Hoofddorp, the Netherlands, 3 July 2020. IGEA Pharma N.V. (SIX: IGPH) today announced that its shareholders followed the recommendations of the company. The minutes of the second annual general meeting is available at https://www.igeapharma.nl/category/information-for-shareholders/
The board of directors (the “Board”) of IGEA Pharma N.V. (the “Company”) hereby invites you to attend the general meeting on 3 July 2020 (the “GM”) at Hoofddorp Transpolis, Polarisavenue 1, 2123 JH Hoofddorp, the Netherlands. The meeting will start at 10:00 hours CEST. Registration will start at 9:30 hours CEST. Due to the current ongoing situation with COVID-19, the Company encourages its shareholders to attend the GM by proxy.
Hoofddorp, the Netherlands, 2 June 2020. IGEA Pharma N.V. (SIX: IGPH) today announced the nomination of Mr. Lieven Baten for election as non-executive director of IGEA at the upcoming general meeting on 3 July 2020. Lieven Baten is a partner at Acalis, with which IGEA has previously signed a strategic partnership for the distribution of its products.
Hoofddorp, the Netherlands, 31 May 2020. IGEA Pharma N.V. (SIX: IGPH) today announced the disclosure of its Annual Report 2019.
Hoofddorp, the Netherlands, 6 May 2020. IGEA Pharma N.V. (SIX: IGPH) today announced that an evaluation by the Histocompatibility Laboratories, Department of Surgery, University of Miami – Miller School of Medicine suggests that the IGEA’s COVID-19 antibody rapid test appears to be superior to an established ELISA procedure in detecting IgM and IgG antibodies.